Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chemnitz
Clinical trial register · Germany

Clinical Trials in Chemnitz, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5081 matching records held by the registry are in this view. Synced 13 Nov 2026, 03:18 UTC
5081
Studies in scope
all four open statuses
2880
Recruiting now
open to new participants
985
Lead sponsors
across recruiting studies
Top sites
Berlin 1591 Hamburg 896 Essen 767 Dresden 717 Heidelberg 626
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca20 Hoffmann-La Roche11 Bristol-Myers Squibb7 AbbVie6 Technische Universität Dresden5 Eli Lilly and Company5 Pfizer5 Universitätsklinikum Hamburg-Eppendorf5 Amgen4 Janssen Research & Development, LLC4 University of Leipzig3 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest3 University of Heidelberg Medical Center3 Incyte Corporation3 Daiichi Sankyo3 Stemline Therapeutics, Inc.2 BeOne Medicines2 Seaport Therapeutics2 GlaxoSmithKline2 Syndax Pharmaceuticals2 Sanofi2 University Hospital Muenster2 EMD Serono Research & Development Institute, Inc.2 Merck Sharp & Dohme LLC2 BioNTech SE2 Show all 82
Site location
Berlin1591 Hamburg896 Essen767 Dresden717 Heidelberg626 Cologne619 Leipzig515 München513 Hanover488 Tübingen457 Bonn424 Düsseldorf409 Munich398 Freiburg im Breisgau392 Erlangen373 Frankfurt369 Münster359 Frankfurt am Main346 Ulm343 Mainz336 Würzburg299 Aachen267 Augsburg248 Kiel236 Lübeck225 Show all 642
All 642 locations
Target enrolment
to

Trials with a site in Chemnitz

167 of 5081 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
Thomas Ernst, Prof. Dr. med.
Phase 2
50
Aachen, Berlin, Chemnitz, Dresden, Hamburg, Hanover, Jena, Leipzig
2026-11
Not yet open
First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma
NCT07844057Small-bowel Adenocarcinoma, Metastatic Disease, Chemotherapy Effect
Annika Kurreck
Phase 2
86
Augsburg, Bad Saarow, Berlin, Chemnitz, Frankfurt, Herne, Landshut, München
2026-10-01
Recruiting
Takeda
Phase 3
324
Freiburg im Breisgau, Heidelberg, Mutlangen, Minden, Koblenz, Chemnitz, Halle, Jena
2026-09-10
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Bad Oldesloe, Bamberg, Berlin, Bielefeld, Bochum, Bremen, Chemnitz, Cologne
2026-08-24
Recruiting
AstraZeneca
Phase 3
7,000
Ahrensburg, Bad Mergentheim, Bad Nenndorf, Berlin, Bonn, Brandenburg an der Havel, Braunschweig, Chemnitz
2026-08-21
Recruiting
Eli Lilly and Company
Phase 3
1,000
Berlin, Chemnitz, Hamburg, Leipzig, Schwerin
2026-08-14
Recruiting
AstraZeneca
Phase 3
1,200
Bad Oeynhausen, Berlin, Chemnitz, Damme, Duisburg, Elsterwerda, Erlangen, Essen
2026-07-06
Recruiting
AstraZeneca
Phase 3
900
Bad Oeynhausen, Berlin, Brandenburg an der Havel, Chemnitz, Duisburg, Erlangen, Frankfurt, Hamburg
2026-07-06
Recruiting
Glycolytic Phenotype (vLapeak) and Magnitude of Skeletal Muscle Hypertrophy After Resistance Training
NCT07721766Healthy Volunteers, Muscle Hypertrophy, Glycolysis, Moderately Trainend
Technical University of Munich
Not applicable
120
München, Cologne, Düsseldorf, Chemnitz, Leipzig
2026-05-04
Recruiting
AstraZeneca
Observational
125
Altenburg, Bad Bramstedt, Bamberg, Berlin, Braunschweig, Chemnitz, Erlangen, Hanover
2026-03-19
Recruiting
Timo Munz
Observational
543
Amberg, Berlin, Chemnitz, Dresden, Duisburg, Freiburg im Breisgau, Hamburg, Kassel
2026-03-02
Recruiting
Eli Lilly and Company
Phase 3
1,000
Aachen, Berlin, Bielefeld, Chemnitz, Mainz, Mannheim, Schwerin, Siegen
2026-02-09
Recruiting
Technische Universität Dresden
Phase 2
220
Aachen, Augsburg, Berlin, Chemnitz, Cologne, Dresden, Frankfurt am Main, Greifswald
2026-01-21
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
München, Frankfurt am Main, Kassel, Georgsmarienhütte, Chemnitz, Halle, Lübeck, Berlin
2026-01-06
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Erlangen, Hanover, Dresden, Berlin, Bochum, Chemnitz, Düsseldorf, Frankfurt
2025-12-31
Recruiting
Ipsen
Observational
150
Aschaffenburg, Berlin, Bonn, Bremen, Chemnitz, Cologne, Dresden, Erlangen
2025-12-17
Recruiting
Federation Francophone de Cancerologie Digestive
Phase 3
324
Chemnitz, Essen, Frankfurt, Hamburg, Jena, Leipzig, München, Rostock
2025-12-15
Recruiting
Janssen Research & Development, LLC
Observational
380
Aschaffenburg, Bielefeld, Bochum, Bremen, Chemnitz, Cologne, Düsseldorf, Essen
2025-12-03
Recruiting
Hoffmann-La Roche
Phase 3
250
Chemnitz, Düsseldorf, Göttingen, Hanover, Rostock, Würzburg
2025-11-27
Recruiting
Syndax Pharmaceuticals
Phase 3
468
Heidelberg, Stuttgart, Tübingen, Braunschweig, Düsseldorf, Herne, Minden, Chemnitz
2025-11-25
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
65
Freiburg im Breisgau, Ulm, Cologne, Essen, Chemnitz, Berlin, Göttingen, Hamburg
2025-11-06
Recruiting
Bristol-Myers Squibb
Phase 2/3
661
Esslingen am Neckar, Stuttgart, Donauwörth, Oldenburg, Cologne, Chemnitz, Kiel, Berlin
2025-11-05
Recruiting
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT07197307Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B
Universität Münster
Phase 2
120
Aachen, Augsburg, Berlin, Bielefeld, Chemnitz, Düsseldorf, Erlangen, Essen
2025-10-31
Recruiting
Universität des Saarlandes
Phase 3
214
Berlin, Chemnitz, Darmstadt, Dresden, Erfurt, Erlangen, Frankfurt am Main, Giessen
2025-10-30
Active, closed
Bristol-Myers Squibb
Phase 2/3
470
München, Frankfurt am Main, Göttingen, Bochum, Chemnitz, Dresden, Berlin, Cologne
2025-10-23
Recruiting
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
NCT07785180Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Stemline Therapeutics, Inc.
Observational
140
Bremen, Chemnitz, Leipzig, Lübeck, Munich, Oldenburg, Würzburg
2025-10-17
By invitation
Seaport Therapeutics
Phase 2
360
Berlin, Schwerin, Bad Homburg, Chemnitz
2025-09-02
Active, closed
Amgen
Phase 3
350
Chemnitz, Cologne, Dresden, Essen, Frankfurt am Main, Gauting, Großhansdorf, Kiel
2025-08-18
Recruiting
GlaxoSmithKline
Phase 3
420
Karlsruhe, Löwenstein, Stuttgart, Augsburg, Chemnitz, Esslingen am Neckar, Heidelberg, Immenhausen
2025-08-11
Recruiting
AstraZeneca
Phase 3
800
Amberg, Chemnitz, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2025-08-01
Recruiting
Pfizer
Phase 3
714
Löwenstein, Ulm, Gröbenzell, Traunstein, Giessen, Kassel, Koblenz, Chemnitz
2025-07-23
Recruiting
Bristol-Myers Squibb
Phase 3
586
Munich, Göttingen, Bad Homburg, Chemnitz, Cologne, Ulm
2025-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Ulm, Detmold, Dortmund, Trier, Homburg, Chemnitz
2025-07-21
Recruiting
Seaport Therapeutics
Phase 2
360
Berlin, Schwerin, Bad Homburg, Chemnitz
2025-06-19
Recruiting
Technische Universität Dresden
Phase 2
76
Aachen, Chemnitz, Dresden, Erlangen, Essen, Frankfurt am Main, Greifswald, Halle
2025-06-17
Active, closed
Incyte Corporation
Phase 3
159
Bad Bentheim, Bonn, Chemnitz, Dresden, Frankfurt, Göttingen, Kiel, Mainz
2025-06-17
Recruiting
MediWound Ltd
Phase 3
216
München, Chemnitz, Berlin, Bochum, Dresden, Erlangen, Kiel
2025-06-01
Recruiting
AstraZeneca
Phase 3
1,220
Aachen, Berlin, Bonn, Chemnitz, Cologne, Dortmund, Dresden, Erlangen
2025-05-06
Active, closed
Novartis Pharmaceuticals
Phase 3
246
Stuttgart, Potsdam, Chemnitz, Leipzig, Berlin, Bielefeld, Gelnhausen, Mannheim
2025-04-30
Recruiting
University of Leipzig
Phase 3
1,960
Alsfeld, Bad Krozingen, Bonn, Chemnitz, Flensburg, Frankfurt a.M., Leipzig, München
2025-04-14
Recruiting
BeOne Medicines
Phase 3
250
Augsburg, Berlin, Chemnitz, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2025-04-10
Recruiting
Gilead Sciences
Phase 3
695
Berlin, Bochum, Chemnitz, Esslingen am Neckar, Hamburg, Löwenstein, Minden, Munich
2025-04-04
Not yet open
App Impact on Quality of Life and Symptoms in PCOS
NCT06912594Polycystic Ovary Syndrome (PCOS)
Endo Health GmbH
Not applicable
220
Chemnitz
2025-04-02
Active, closed
Hoffmann-La Roche
Phase 2
162
Bad Bentheim, Chemnitz, Hamburg
2025-04-01
Not yet open
Pre-Operative Treatment in REseCTable COlon CanceR
NCT06899477Colo-rectal Cancer, Colon Cancer, Colon Carcinoma
DrugsMFOLFOXIRI·MFOLFOX6·Folfox·Irinotecan
Dominik Paul Modest
Phase 3
714
Berlin, Berlin-Spandau, Chemnitz, Cologne, Dessau, Dortmund, Frankfurt, Hamburg
2025-04
Recruiting
AstraZeneca
Phase 3
600
Berlin, Chemnitz, Dessau, Dresden, Düsseldorf, Essen, Hamburg, Kassel
2025-03-27
Recruiting
Eli Lilly and Company
Phase 3
700
Berlin, Chemnitz, Cologne, Erfurt, Gauting, Georgsmarienhütte, Großhansdorf, Halle
2025-03-27
Active, closed
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1/2
36
Berlin, Chemnitz, Essen, Frankfurt am Main, Halle, Hamburg, Heidelberg, Jena
2025-03-25
Recruiting
Christian Buske
Phase 2
80
Bielefeld, Chemnitz, Kempten, Kiel, Koblenz, Landshut, Mönchengladbach, Mutlangen
2025-03-21
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Munich, Hanover, Chemnitz, Leipzig, Magdeburg, Kiel, Berlin, Hamburg
2025-03-12
Recruiting
BeOne Medicines
Phase 3
300
Chemnitz, Frankfurt am Main, Halle, Mutlangen, München, Siegen, Stuttgart
2025-03-05
Active, closed
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
126
Aachen, Amberg, Augsburg, Bad Saarow, Berlin, Bielefeld, Chemnitz, Dortmund
2025-03-03
Recruiting
AstraZeneca
Phase 3
840
Augsburg, Bad Saarow, Berlin, Braunschweig, Chemnitz, Düsseldorf, Erlangen, Essen
2025-03-01
Recruiting
Summit Therapeutics
Phase 3
780
Chemnitz, Esslingen am Neckar, Gauting, Giesen, Halle, Herne, Karlsruhe, Minden
2025-02-27
Recruiting
Daiichi Sankyo
Phase 3
726
Berlin, Chemnitz, Dresden, Frankfurt am Main, Hamburg, Heidelberg, Leipzig, München
2025-02-27
Active, closed
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
2,000
Aachen, Ahaus, Alsfed, Bad Homburg, Berlin, Burg, Chemnitz, Detmold
2025-02-12
Active, closed
AbbVie
Phase 3
468
Erbach im Odenwald, Westerstede, Greifswald, Bielefeld, Ibbenbueren, Siegen, Chemnitz, Leipzig
2025-02-10
Recruiting
BioNTech SE
Phase 3
621
Berlin, Bonn, Chemnitz, Esslingen am Neckar, Gauting, Gera, Großhansdorf, Halle
2025-02-03
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Aachen, Berlin, Braunschweig, Chemnitz, Dresden, Düsseldorf, Essen, Göttingen
2025-01-28
Recruiting
BioNTech SE
Phase 2/3
1,580
Aachen, Berlin, Chemnitz, Düsseldorf, Erlangen, Esslingen am Neckar, Gauting, Gera
2025-01-07
Recruiting
GlaxoSmithKline
Phase 3
520
Jena, Lübeck, Chemnitz, Cologne, Dresden, Hamburg, Hanover, Mainz
2024-12-16
Recruiting
The PERSEVERE Study
NCT06588634Pulmonary Embolism, Pulmonary Thromboembolism
Inari Medical
Not applicable
200
Kiel, Berlin, Chemnitz, Dresden, Mainz, München, Regensburg
2024-12-16
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Berlin, Chemnitz, Essen, Jena, Würzburg
2024-11-27
Recruiting
AstraZeneca
Phase 3
1,160
Bad Berka, Berlin, Bielefeld, Bochum, Chemnitz, Cologne, Esslingen am Neckar, Frankfurt
2024-11-27
Recruiting
AstraZeneca
Phase 3
1,160
Bad Berka, Berlin, Bielefeld, Bochum, Chemnitz, Cologne, Essen, Esslingen am Neckar
2024-11-18
Active, closed
Incyte Corporation
Phase 3
346
Aachen, Buxtehude, Chemnitz, Darmstadt, Dresden, Frankfurt am Main, Göttingen, Magdeburg
2024-10-10
Active, closed
AbbVie
Phase 2
309
Berlin, Chemnitz, Dresden, Essen, Frankfurt am Main
2024-10-07
Active, closed
Celgene
Phase 2
95
Regensburg, Chemnitz, Dresden
2024-08-30
Recruiting
Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma
NCT06175845Cholangiocarcinoma, Klatskin Tumor, Bile Duct Cancer, Liver Cancer
Universitätsklinikum Hamburg-Eppendorf
Not applicable
130
Berlin, Bonn, Chemnitz, Essen, Hamburg, Hanover, Heidelberg, Lübeck
2024-08-30
Recruiting
Amgen
Phase 3
450
Berlin, Chemnitz, Dresden, Essen, Frankfurt am Main, Hamburg, Ludwigsburg, München
2024-07-17
Recruiting
AstraZeneca
Observational
600
Bad Homburg, Berlin, Bremen, Celle, Chemnitz, Cologne, Deggendorf, Frankfurt
2024-06-28
Recruiting
A Registry-study of ELZONRIS in Participants With BPDCN
NCT07785154Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
DrugTagraxofusp
Stemline Therapeutics, Inc.
Observational
80
Augsburg, Bielefeld, Chemnitz, Frankfurt, Freiburg im Breisgau, Halle, Hamburg, Kiel
2024-06-26
Active, closed
Ivy Brain Tumor Center
Phase 3
450
Heidelberg, Mannheim, Tübingen, Regensburg, Bonn, Chemnitz, Leipzig, Berlin
2024-06-19
Active, closed
The Lymphoma Academic Research Organisation
Phase 3
790
Amberg, Bamberg, Berlin, Bremen, Chemnitz, Düsseldorf, Frankfurt, Freiburg im Breisgau
2024-06-07
Active, closed
Janssen Research & Development, LLC
Phase 1
108
Chemnitz, Hamburg, Heidelberg, Würzburg
2024-06-07
Recruiting
Curasight
Phase 2
168
Chemnitz, Düsseldorf, Hamburg, Munich
2024-06-01
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
DrugPegozafermin
Hoffmann-La Roche
Phase 3
1,800
Chemnitz, Frankfurt, Freiburg im Breisgau, Hanover, Homburg, Münster
2024-05-24
Active, closed
AbbVie
Phase 3
421
Freiburg im Breisgau, Karlsruhe, Chemnitz, Berlin, Frankfurt am Main, Hamburg
2024-05-19
Recruiting
AstraZeneca
Phase 3
3,850
Bad Nauheim, Bechhofen, Berlin, Bernau bei Berlin, Chemnitz, Coburg, Dresden, Elsterwerda
2024-04-12
Active, closed
Amgen
Phase 3
434
Heidelberg, Bad Doberan, Greifswald Hansestadt, Chemnitz, Hamburg
2024-04-08
Recruiting
Technische Universität Dresden
Phase 2
146
Essen, Aachen, Augsburg, Chemnitz, Cologne, Dresden, Erlangen, Frankfurt am Main
2024-04-07
Active, closed
University of Heidelberg Medical Center
Phase 3
411
Aachen, Augsburg, Bad Saarow, Berlin, Bielefeld, Bonn, Braunschweig, Chemnitz
2024-04-05
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
Hoffmann-La Roche
Phase 3
1,350
Chemnitz, Frankfurt am Main, Freiburg im Breisgau, Hanover, Homburg, Münster
2024-03-13
Recruiting
Technische Universität Dresden
Observational
500
Aachen, Chemnitz, Dresden, Düsseldorf, Essen, Göttingen, Hamburg, Jena
2024-03-13
Recruiting
University Hospital Muenster
Observational
2,000
Chemnitz, Aachen, Greifswald, Leipzig, Münster, Tübingen
2024-03-01
Active, closed
CarThera
Phase 3
560
Berlin, Chemnitz, Cologne, Dresden, Essen, Münster
2024-01-29
Active, closed
Sanofi
Observational
110
Adernach, Berlin, Chemnitz, Düren, Düsseldorf, Hamburg, Leipzig, Mainz
2023-12-27
Recruiting
Eli Lilly and Company
Phase 3
1,264
Berlin, Chemnitz, Cologne, Erfurt, Freiburg im Breisgau, Gauting, Georgsmarienhütte, Großhansdorf
2023-12-21
Recruiting
Janssen-Cilag Ltd.
Observational
900
Chemnitz, Dresden, Hamburg, Hanover, Heidelberg, Nuremberg, Würzburg
2023-12-18
Active, closed
Syndax Pharmaceuticals
Phase 2
145
Konstanz, Munich, Hanover, Chemnitz, Frankfurt am Main, Gauting, Rosenheim
2023-12-11
Recruiting
Amgen
Phase 3
750
Chemnitz, Gauting, Göttingen, Kempten, München
2023-11-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Freiburg, Göttingen, Essen, Chemnitz, Dresden, Hamburg
2023-11-12
Active, closed
Hoffmann-La Roche
Phase 3
1,130
Berlin, Brandenburg an der Havel, Chemnitz, Cologne, Düsseldorf, Erlangen, Essen, Frankfurt
2023-09-18
By invitation
Disc Medicine, Inc
Phase 2/3
230
Berlin, Chemnitz
2023-08-31
Active, closed
AstraZeneca
Phase 3
142
Chemnitz, Hanover
2023-08-16
Recruiting
Universitätsklinikum Hamburg-Eppendorf
Phase 1/2
45
Hamburg, Chemnitz, Heidelberg, Lübeck, Ulm
2023-06-28
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Ulm, Augsburg, Bayreuth, Erlangen, Munich, Cottbus, Hamburg, Chemnitz
2023-06-22
Active, closed
University of Leipzig
Phase 2
45
Berlin, Chemnitz, Cottbus, Dresden, Heidelberg, Leipzig, Mönchengladbach, München
2023-05-17
Active, closed
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
125
Magdeburg, Berlin, Bochum, Chemnitz, Düsseldorf, Erlangen, Essen, Halle
2023-03-20
Active, closed
Sanofi
Observational
572
Aachen, Ahaus, Andernach, Berlin, Braunschweig, Buxtehude, Chemnitz, Cologne
2023-03-07
Active, closed
Bristol-Myers Squibb
Phase 3
516
Tübingen, Munich, Dresden, Lübeck, Chemnitz, Cologne, Erlangen, Planegg
2023-01-12
Active, closed
Daiichi Sankyo
Phase 3
1,233
Berlin, Chemnitz, Essen, Esslingen am Neckar, Freiburg im Breisgau, Giessen, Mannheim, Munich
2023-01-11
Recruiting
GBG Forschungs GmbH
Phase 2
170
Essen, Augsburg, Berlin, Bielefeld, Chemnitz, Cologne, Dessau, Dresden
2023-01-02
Recruiting
Promedon
Observational
140
Chemnitz, Erfurt, Freiburg im Breisgau, Kassel, Leipzig, Mannheim, Tettnang
2022-12-19
Recruiting
Greenwich LifeSciences, Inc.
Phase 3
2,250
Augsburg, Bayreuth, Berlin, Bottrop, Braunschweig, Bremen, Chemnitz, Dessau
2022-12-16
Active, closed
Janssen Research & Development, LLC
Phase 3
214
Chemnitz, Hamburg, Tübingen
2022-12-15
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
Berlin, Chemnitz, Cologne, Dresden, Essen, Münster
2022-12-13
Recruiting
GMMG Multiple Myeloma Registry
NCT07111884Multiple Myeloma
Prof. Dr. Hartmut Goldschmidt
Observational
999
Berlin, Bielefeld, Bochum, Bonn, Chemnitz, Cologne, Darmstadt, Düsseldorf
2022-12-08
Recruiting
University of Heidelberg Medical Center
Phase 2
160
Berlin, Chemnitz, Dresden, Düsseldorf, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel
2022-12-01
Recruiting
Pfizer
Phase 3
1,060
Freiburg im Breisgau, Tübingen, Ulm, Mainz, Aachen, Braunschweig, Chemnitz, Hamburg
2022-11-10
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Munich, München, Hanover, Leipzig, Amberg, Berlin, Chemnitz, Dresden
2022-10-24
Active, closed
University of Leipzig
Observational
60
Berlin, Chemnitz, Dresden, Düsseldorf, Jena, Leipzig, Mainz, Mannheim
2022-10-11
Recruiting
EMD Serono Research & Development Institute, Inc.
Observational
700
Chemnitz, Großhansdorf, Heidelberg, Löwenstein
2022-10-04
Recruiting
AGO Study Group
Phase 3
970
Amberg, Augsburg, Bad Homburg, Berlin, Bielefeld, Brandenburg an der Havel, Bremen, Chemnitz
2022-09-13
Active, closed
AstraZeneca
Phase 3
341
Berlin, Chemnitz, Frankfurt A. Main, Gauting, Immenhausen, Löwenstein, München, Münster
2022-08-03
Active, closed
Gilead Sciences
Phase 2
193
Berlin, Chemnitz, Cologne, Esslingen am Neckar, Frankfurt, Gauting, Großhansdorf, Halle
2022-05-30
Active, closed
Hoffmann-La Roche
Phase 3
1,300
Tübingen, Ulm, Bayreuth, Munich, Westerstede, Düsseldorf, Chemnitz, Leipzig
2022-05-03
Active, closed
European Myeloma Network B.V.
Phase 3
117
Chemnitz, Düsseldorf, Greifswald, Hamburg
2022-04-19
Active, closed
AstraZeneca
Phase 3
760
Bonn, Chemnitz, Dresden, Düsseldorf, Frankfurt, Göttingen, Hamburg, Hanover
2022-03-28
Active, closed
Pfizer
Phase 3
854
Würzburg, Mainz, Leipzig, Kiel, Berlin, Chemnitz, Essen, München
2022-03-25
Active, closed
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
NCT05153226Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation, AML, MDS
DrugCyclophosphamide
DKMS gemeinnützige GmbH
Phase 3
640
Aachen, Augsburg, Chemnitz, Cologne, Dortmund, Dresden, Düsseldorf, Essen
2022-03-02
Active, closed
AstraZeneca
Phase 3
791
Berlin, Berlin-Zehlendorf, Braunschweig, Chemnitz, Cologne, Erlangen, Essen, Giessen
2022-02-18
Recruiting
Heidelberg Pharma AG
Phase 1/2
78
Berlin, Chemnitz, Cologne, Hamburg, Heidelberg, Kiel, Lübeck, Mainz
2022-02-07
Active, closed
NewAmsterdam Pharma
Phase 3
9,541
Bad Homburg, Berlin, Bremen, Chemnitz, Dortmund, Dresden, Elsterwerda, Erfurt
2022-02-07
Recruiting
Dominik Paul Modest
Phase 3
507
Amberg, Bad Saarow, Bayreuth, Berlin, Bochum, Bonn, Bremen, Chemnitz
2021-12-06
Active, closed
Hoffmann-La Roche
Phase 3
660
Bad Berka, Berlin, Chemnitz, Essen, Georgsmarienhütte, Großhansdorf, Halle, Immenhausen
2021-11-18
Recruiting
Pfizer
Phase 3
893
Ulm, Würzburg, Berlin, Braunschweig, Chemnitz, München
2021-10-04
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
333
Chemnitz, Frankfurt, Hanover, Kiel, Leipzig, Magdeburg, Münster, Tübingen
2021-09-22
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Chemnitz, Essen, Kerpener, Koelner Platz 1, Leipzig, Rostock, Würzburg
2021-09-20
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Karlsruhe, Augsburg, Berlin, Chemnitz, Erlangen, Essen, Georgsmarienhütte, Hamburg
2021-08-27
Active, closed
Inventiva Pharma
Phase 3
1,000
Wiesbaden, Mainz, Homburg, Chemnitz, Dresden, Leipzig, Lübeck, Berlin
2021-08-19
Recruiting
University Medicine Greifswald
Observational
3,000
Aachen, Berlin, Bonn, Braunschweig, Chemnitz, Cologne, Cottbus, Düsseldorf
2021-08-06
Active, closed
Boston Scientific Corporation
Phase 4
544
Aachen, Bielefeld, Bonn, Chemnitz, Freiburg im Breisgau, Immenstädt, Lübeck, Mainz
2021-08-02
Active, closed
AstraZeneca
Phase 3
315
Ansbach, Augsburg, Bonn, Chemnitz, Dresden, Erlangen, Essen, Freiburg im Breisgau
2021-06-30
Active, closed
Incyte Corporation
Phase 3
899
Aachen, Augsburg, Berlin, Bonn, Chemnitz, Cottbus, Göttingen, Halle
2021-05-11
Recruiting
Alnylam Pharmaceuticals
Observational
150
Berlin, Chemnitz, Würzburg
2021-04-26
Recruiting
University Hospital Heidelberg
Phase 3
406
Heidelberg, Berlin, Bochum, Bonn, Chemnitz, Cologne, Düsseldorf, Frankfurt
2021-04-07
Active, closed
Bristol-Myers Squibb
Phase 1/2
216
Erding, Essen, Chemnitz, Halle, Lübeck
2021-03-22
Active, closed
Sellas Life Sciences Group
Phase 3
127
Chemnitz, Leipzig, Rostock
2021-02-08
Active, closed
Daiichi Sankyo
Phase 3
1,600
Augsburg, Berlin, Bielefeld, Böblingen, Braunschweig, Bremen, Chemnitz, Cologne
2020-12-04
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Immenstadt im Allgäu, Amberg, Augsburg, Bad Homburg, Berlin, Braunschweig, Chemnitz, Cologne
2020-12-02
Active, closed
Hoffmann-La Roche
Phase 3
992
Berlin, Chemnitz, Dresden, Essen, Georgsmarienhütte, Göttingen, Hamburg, Hanover
2020-10-09
Recruiting
Technische Universität Dresden
Phase 1/2
214
München, Essen, Aachen, Augsburg, Chemnitz, Dresden, Frankfurt am Main, Halle
2020-09-04
Active, closed
AbbVie
Phase 3
330
Mannheim, Mutlangen, Augsburg, Rostock, Bochum, Chemnitz, Dresden, Hamburg
2020-08-31
Active, closed
AstraZeneca
Phase 3
805
Bonn, Chemnitz, Dresden, Leipzig
2020-05-05
Recruiting
Terumo Aortic Global Endovascular Registry
NCT04246463Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
Vascutek Ltd.
Observational
1,000
Augsburg, Berlin, Chemnitz, Freiburg im Breisgau, Göttingen, Lingen, Münster, Tübingen
2019-12-17
Recruiting
Pierre Fabre Pharma GmbH
Observational
750
Ahaus, Aschaffenburg, Augsburg, Berlin, Bremerhaven, Buxtehude, Chemnitz, Donauwörth
2019-10-17
Recruiting
University Hospital Muenster
Phase 3
683
Aachen, Augsburg, Berlin, Bielefeld, Bonn, Braunschweig, Bremen, Chemnitz
2019-08-23
Active, closed
University of Jena
Phase 2
125
Aachen, Berlin, Bonn, Bremen, Chemnitz, Dresden, Erlangen, Essen
2019-08-19
Active, closed
AbbVie
Phase 3
265
Stuttgart, Tübingen, Würzburg, Chemnitz, Kiel, Jena, Berlin, Hamburg
2018-10-22
Active, closed
University of Heidelberg Medical Center
Phase 3
662
Aachen, Bad Saarow, Berlin, Bielefeld, Bochum, Bonn, Braunschweig, Chemnitz
2018-10-18
Active, closed
Hoffmann-La Roche
Phase 3
257
Chemnitz, Georgsmarienhütte, Heidelberg, Immenhausen
2018-08-16
Active, closed
Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer
NCT03503799Primary Invasive Breast Cancer, Estrogen Receptor Positive Tumor, Human Epidermal Growth Factor Receptor 2 Negative Tumor
North Eastern German Society of Gynaecological Oncology
Observational
1,191
München, Berlin, Ansbach, Bremerhaven, Chemnitz, Dresden, Düsseldorf, Ebersberg
2018-07-17
Recruiting
Martin Schrappe
Phase 3
5,000
Aachen, Augsburg, Berlin, Braunschweig, Chemnitz, Cologne, Cottbus, Datteln
2018-07-15
Active, closed
Endurant CHevAr New Indication Trial: ENCHANT
NCT03320252AAA - Abdominal Aortic Aneurysm
Medtronic Cardiovascular
Observational
150
Chemnitz, Essen, Frankfurt am Main, Heidelberg, Münster
2017-10-26
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
Chemnitz, Gauting, Heidelberg, Wiesbaden
2017-09-22
Active, closed
Universitätsklinikum Hamburg-Eppendorf
Phase 2
246
Berlin, Bielefeld, Bonn, Chemnitz, Cologne, Eschweiler, Essen, Hamburg
2017-08-15
Active, closed
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
146
Essen, Chemnitz, Berlin, Hanover, Leipzig, München, Ulm
2017-06-26
Active, closed
REDUCE LAP-HF III Corvia Protocol 1701
NCT03191656Heart Failure
Corvia Medical
Observational
500
Bad Nauheim, Bad Oeynhausen, Bad Segeberg, Berlin, Chemnitz, Cologne, Detmold, Dresden
2017-03-12
Recruiting
CVRx, Inc.
Observational
500
Hamburg, Bad Oeynhausen, Berlin, Bernau, Chemnitz, Cologne, Detmold, Dresden
2016-12-13
Active, closed
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
DrugTepotinib
EMD Serono Research & Development Institute, Inc.
Phase 2
337
Leipzig, Berlin, Chemnitz, Dresden, Erfurt, Gauting, Gera, Göttingen
2016-09-13
Active, closed
European LeukemiaNet
Phase 2
75
Freiburg im Breisgau, Mannheim, München, Hannover, Aachen, Bayreuth, Chemnitz, Esslingen am Neckar
2016-09
Active, closed
AbbVie
Phase 3
1,629
Cologne, Herne, Rendsburg, Chemnitz, Hamburg, Munich
2015-12-01
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Braunschweig, Chemnitz, Dessau, Frankfurt, Gronau, Jena, Münster, Nürtingen
2015-11-19
Active, closed
Eli Lilly and Company
Phase 3
545
Gerlingen, Heidelberg, Cologne, Chemnitz, Halle, Großhansdorf, Berlin
2015-05-06
Recruiting
International HIT-MED Registry (I-HIT-MED)
NCT02417324Childhood Brain Tumor
Universitätsklinikum Hamburg-Eppendorf
Observational
500
Aachen, Augsburg, Berlin, Bielefeld, Braunschweig, Bremen, Chemnitz, Cologne
2015-01
Active, closed
Universitätsklinikum Hamburg-Eppendorf
Phase 2/3
360
Aachen, Augsburg, Berlin, Bielefeld, Bonn, Braunschweig, Bremen, Chemnitz
2014-06
Rows per page Showing 1–167 of 167
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 15 November 2026. https://priyalifescience.com/clinical-trials-germany/city/chemnitz

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,081 studies in total at the last sync on 13 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 167 of those studies with a site in Chemnitz.

How many clinical trials are recruiting in Chemnitz?

90 of the 167 studies on this page are recruiting new participants as of the 13 Nov 2026, 03:18 UTC sync. A further 3 have not yet opened recruitment, 72 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Chemnitz), 167 studies
PhaseStudiesRecruitingShare
Phase 3934855.7%
Phase 2271216.2%
Observational261915.6%
Phase 2/3955.4%
Phase 1/2633.6%
Not applicable432.4%
Phase 1100.6%
Phase 4100.6%

Most active sponsors

Lead sponsors with the most studies (Chemnitz)
Lead sponsorStudiesRecruiting
AstraZeneca2014
Hoffmann-La Roche113
Bristol-Myers Squibb73
AbbVie60
Eli Lilly and Company54
Pfizer54
Technische Universität Dresden55
Universitätsklinikum Hamburg-Eppendorf53
Amgen42
Janssen Research & Development, LLC41
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.